NCT05292846View on ClinicalTrials.gov

Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures

PHASE4RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 20, 2022

Primary Completion Date

February 20, 2024

Study Completion Date

April 20, 2024

Conditions
Coronary Artery DiseaseBleedingDirect Acting Anticoagulant Adverse Reaction
Interventions
DRUG

Direct-acting oral anticoagulation

Apixaban Dabigatran Edoxaban Rivaroxaban

Trial Locations (4)

20089

NOT_YET_RECRUITING

Humanitas Research Hospital, Rozzano

46026

RECRUITING

Hospital Universitario y Politécnico La Fe, Valencia

Unknown

RECRUITING

Hospital del Mar, Barcelona

RECRUITING

Hospital La Paz, Madrid

All Listed Sponsors
lead

Hospital Universitario La Fe

OTHER

NCT05292846 - Uninterrupted Direct-acting Oral Anticoagulation in Patients Undergoing Transradial Percutaneous Coronary Procedures | Biotech Hunter | Biotech Hunter